• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

7-Bromoimidazo[1,2-a]pyridine Hydrochloride (CAS 1252686-44-4): A Versatile Building Block in Pharmaceutical Research

7-Bromoimidazo[1,2-a]pyridine hydrochloride (CAS 1252686-44-4) is an important heterocyclic compound that has gained significant attention in medicinal chemistry and drug discovery. This brominated imidazopyridine derivative serves as a valuable scaffold for the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and other therapeutic agents.

The growing interest in imidazo[1,2-a]pyridine derivatives stems from their diverse pharmacological properties and their presence in several FDA-approved drugs. Researchers are particularly focused on 7-position modified imidazopyridines due to their enhanced binding affinity to various biological targets. The bromo substituent at position 7 makes this compound an excellent intermediate for further functionalization through cross-coupling reactions.

Recent studies highlight the importance of 7-bromoimidazo[1,2-a]pyridine HCl in the development of antiviral and anticancer compounds. Its molecular structure allows for efficient interactions with various enzyme active sites, making it a preferred choice for structure-activity relationship (SAR) studies. The hydrochloride salt form improves solubility and handling characteristics, which are crucial factors in pharmaceutical applications.

In synthetic chemistry, CAS 1252686-44-4 serves as a key building block for palladium-catalyzed coupling reactions such as Suzuki, Buchwald-Hartwig, and Sonogashira reactions. This versatility has made it particularly valuable in the rapid generation of compound libraries for high-throughput screening. The compound's stability under various reaction conditions contributes to its popularity among medicinal chemists.

The pharmaceutical industry's increasing focus on targeted therapies has driven demand for specialized heterocyclic compounds like 7-bromoimidazo[1,2-a]pyridine hydrochloride. Its applications extend to the development of JAK inhibitors, BTK inhibitors, and other small molecule modulators of cellular signaling pathways. Researchers are particularly interested in its potential for creating selective kinase inhibitors with improved safety profiles.

Quality control of 7-bromoimidazo[1,2-a]pyridine HCl typically involves HPLC analysis, mass spectrometry, and NMR spectroscopy to ensure high purity standards. The compound's characterization data is well-documented in scientific literature, facilitating its use in regulated pharmaceutical research. Proper storage conditions (typically 2-8°C in airtight containers) help maintain its stability over extended periods.

Recent advancements in synthetic methodology have improved the production efficiency of imidazo[1,2-a]pyridine bromides, making them more accessible for research purposes. The development of greener synthetic routes has been a particular focus, aligning with the pharmaceutical industry's sustainability initiatives. These improvements have reduced production costs while maintaining high purity standards.

The global market for pharmaceutical intermediates like 7-bromoimidazo[1,2-a]pyridine hydrochloride has shown steady growth, driven by increased R&D investment in small molecule therapeutics. Contract research organizations and academic institutions represent significant consumers of this compound, utilizing it in both discovery and optimization phases of drug development programs.

Safety considerations for handling CAS 1252686-44-4 include standard laboratory precautions such as proper ventilation, personal protective equipment, and avoidance of direct contact. While not classified as highly hazardous, prudent handling practices are recommended for all chemical substances in research settings. Material safety data sheets provide detailed handling instructions for this compound.

Future research directions for 7-bromoimidazo[1,2-a]pyridine derivatives include exploration of their potential in neurodegenerative disease treatment and immune modulation. The compound's versatility continues to inspire novel synthetic approaches and biological evaluations, ensuring its ongoing relevance in pharmaceutical innovation. Its role in fragment-based drug discovery approaches is particularly promising for addressing challenging therapeutic targets.

Analytical method development for imidazo[1,2-a]pyridine-based compounds has advanced significantly, with LC-MS/MS techniques now enabling precise quantification in biological matrices. These analytical capabilities support pharmacokinetic studies and metabolite identification efforts for drug candidates derived from this chemical scaffold.

The intellectual property landscape surrounding 7-bromoimidazo[1,2-a]pyridine hydrochloride applications continues to evolve, with numerous patents filed for novel derivatives and their therapeutic uses. This active patent activity reflects the compound's importance in current drug discovery efforts and its potential for addressing unmet medical needs across various disease areas.

In conclusion, 7-bromoimidazo[1,2-a]pyridine hydrochloride (CAS 1252686-44-4) represents a strategically important intermediate in modern pharmaceutical research. Its unique structural features, synthetic versatility, and biological relevance ensure its continued utilization in the discovery and development of innovative therapeutic agents. As drug discovery paradigms evolve, this compound is likely to maintain its position as a valuable tool for medicinal chemists worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)